SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Ghost Tree Capital, LLC

CIK 0001595851 · 667 MADISON AVENUE, 5TH FLOOR, SUITE 12, NEW YORK, NY, 10065 · 6467790120

Reported Value
$477M
Q2 2019
Positions
43
Filings on Record
32
2019–present window
Filed
Aug 14, 2019
original filing

Summary

Ghost Tree Capital, LLC reported $477M in U.S.-listed holdings across 43 positions for Q2 2019.

Its largest position, SRPT, represents 9.2% of the portfolio.

Compared with Q1 2019, the fund opened 14 new positions and exited 10.

Portfolio Metrics

Turnover
+32.5%
vs prior filed quarter
Top-10 Concentration
+50.4%
share of reported value
Largest Position
+9.2%
Sarepta Therapeutics
New / Exited
14 / 10
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $285MQ4 ’18Q1 ’19: $369MQ2 ’19: $477MQ3 ’19: $394MQ3 ’19Q4 ’19: $529MQ1 ’20: $377MQ2 ’20: $379MQ2 ’20Q3 ’20: $346MQ4 ’20: $449MQ1 ’21: $425MQ1 ’21Q2 ’21: $364MQ3 ’21: $342MQ4 ’21: $279MQ4 ’21Q1 ’22: $461MQ2 ’22: $192MQ3 ’22: $356MQ3 ’22Q4 ’22: $234MQ1 ’23: $338MQ2 ’23: $303MQ2 ’23Q3 ’23: $304MQ4 ’23: $306MQ1 ’24: $361MQ1 ’24Q2 ’24: $319MQ3 ’24: $331Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 71.0%ETP: 17.7%Other: 7.5%ADR: 3.7%
  • Common Stock · 71.0% · $339M
  • ETP · 17.7% · $85M
  • Other · 7.5% · $36M
  • ADR · 3.7% · $18M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SRPTSAREPTA THERAPEUTICS INCNEW+290.0K290.0K+$44M$44M
SPDR SERIES TRUSTNEW+500.0K500.0K+$40M$40M
NDQINVESCO QQQ TRNEW+200.0K200.0K+$36M$36M
ARGXARGENX SENEW+100.0K100.0K+$14M$14M
MISTMILESTONE PHARMACEUTICALS INNEW+240.0K240.0K+$7M$7M
PFEPFIZER INCNEW+150.0K150.0K+$6M$6M
ZYMEUSDZYMEWORKS INCNEW+275.0K275.0K+$6M$6M
ONCEEURSPARK THERAPEUTICS INCNEW+50.0K50.0K+$5M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

39 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SRPTSAREPTA THERAPEUTICS INChistory →COM9.23%$44M290.0K
22655787DBLUEPRINT MEDICINES CORPhistory →COM7.41%$35M375.0K
3MRTXEURMIRATI THERAPEUTICS INChistory →COM7.23%$35M335.0K
4ASCENDIS PHARMA A SSPONSORED ADR5.43%$26M225.0K
5AXSMAXSOME THERAPEUTICS INChistory →COM4.58%$22M850.0K
6ACADACADIA PHARMACEUTICALS INChistory →COM4.20%$20M750.0K
7AM6AMICUS THERAPEUTICS INChistory →COM3.79%$18M1.45M
8GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM3.30%$16M300.0K
9ARGXARGENX SEhistory →SPONSORED ADR2.97%$14M100.0K
10ALNYALNYLAM PHARMACEUTICALS INChistory →COM2.28%$11M150.0K
11BCRXBIOCRYST PHARMACEUTICALShistory →COM1.98%$9M2.50M
12RARXEURRA PHARMACEUTICALS INChistory →COM1.89%$9M300.0K
13FXFINVESCO CURNCYSHS SWISS FRANhistory →SWISS FRANC1.83%$9M92.2K
14IMMUIMMUNOMEDICS INChistory →COM1.74%$8M600.0K
15CYMABAY THERAPEUTICS INCCOM1.50%$7M1.00M
16RCKTROCKET PHARMACEUTICALS INChistory →COM1.45%$7M460.0K
174XC1KALVISTA PHARMACEUTICALS INChistory →COM1.39%$7M300.0K
18VRAYQVIEWRAY INChistory →COM1.38%$7M750.0K
19MISTMILESTONE PHARMACEUTICALS INhistory →COM1.36%$7M240.0K
20MNTAMOMENTA PHARMACEUTICALS INChistory →COM1.30%$6M500.0K
21ZYMEUSDZYMEWORKS INChistory →COM1.27%$6M275.0K
22EPZMEUREPIZYME INChistory →COM1.22%$6M465.0K
23SG7SAGE THERAPEUTICS INChistory →COM1.15%$5M30.0K
24ONCEEURSPARK THERAPEUTICS INChistory →COM1.07%$5M50.0K
25ARVNARVINAS INChistory →COM1.04%$5M225.0K
26BIOHAVEN PHARMACTL HLDG CO LCOM0.92%$4M100.0K
27KDMNKADMON HLDGS INCCOM0.91%$4M2.10M
28CHRSCOHERUS BIOSCIENCES INCCOM0.81%$4M175.0K
29DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.78%$4M235.0K
30IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.77%$4M150.0K
31ORTXUSDORCHARD THERAPEUTICS PLCADS0.71%$3M242.9K
32CHMACHIASMA INCCOM0.63%$3M400.0K
33UNIQURE NVSHS0.57%$3M35.0K
34HOMOLOGY MEDICINES INCCOM0.51%$2M125.0K
35PTGXPROTAGONIST THERAPEUTICS INCCOM0.51%$2M200.0K
36ODONATE THERAPEUTICS INCCOM0.50%$2M65.0K
37ARQLUSDARQULE INCCOM0.46%$2M200.0K
38SOLID BIOSCIENCES INCCOM0.12%$575,000100.0K
39ALLKGUSDALLAKOS INCCOM0.10%$455,00010.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$331M54Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$319M63Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$361M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$306M52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$304M70Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$303M57Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$338M58May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$234M35Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$356M44Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$192M34Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$461M42May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$279M47Feb 16, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M60Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M52Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$425M50May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$449M43Feb 18, 2021RESTATEMENTchanges · EDGAR ↗
Q3 2020$346M47Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$379M43Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$377M49May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$529M53Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$394M44Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$477M43Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$369M39May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$285M39Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.